Navigation Links
GVAX in Medical News

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

Cell Genesys, Inc. (Nasdaq: CEGE) today announced follow-up data from a Phase 2 clinical trial of GVAX immunotherapy for pancreatic cancer which was conducted by the Johns Hopkins Sidney Kimmel Cancer Center. The trial enrolled 60 patients with operable pancreatic cancer who received GVAX after su...

Experimental Cancer Vaccines Show Promise

...ented Tuesday at the American Association for Cancer Research annual meeting, in San Diego. A second study, out of the Netherlands, found that the gvax vaccine stimulated a significant immune response in men with prostate cancer. Five out of six participants receiving the highest dose of vaccine showe...

Immunotherapy: enlisting the immune system to fight cancer

...ic hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilumumab: ...phase I trial, they observed that a combination of gvax immunotherapy with ipilimumab lowered prostate-spe...s. Higher doses of ipilimumab combined with the gvax vaccine is showing a lot of success in increasing ...

Cell Genesys to Present at the Cowen and Company and the Lehman Brothers Healthcare Investor Conferences

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Reports Fourth Quarter and Year-End 2007 Results

... potential association between immune responses to gvax immunotherapy for prostate cancer and increase...irst of two ongoing Phase 3 clinical trials of gvax immunotherapy for prostate cancer, completed a ... Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials ...

Combo Treatment Best for Melanoma, Advanced Ovarian Cancer

...ce a protein called GVAX. When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting a more energetic attack o...mune response spurred by the vaccine, researchers studied whether combining gvax vaccines with monoclonal antibody therapy could lengthen remissions and que...

Vaccine/antibody therapy effective, milder side effects in melanoma and ovarian cancer

... When the cells are then re-infused into patients, gvax acts like a siren to the immune system, prompting ... researchers have begun studying whether combining gvax vaccines with monoclonal antibody therapy could le... patients who had previously been immunized with a gvax vaccine. The new study, a joint effort of Dana-...
GVAX in Medical Technology

Cell Genesys Reports Association Between Immune Response and Patient Survival in Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Feb. 15 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today reports the results of an analysis examining the potential association between immune responses to GVAX immunotherapy for prostate cancer and increased patient survival in a Phase 2 trial i...

Interim Analysis Supports Continuation of Cell Genesys' VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer

Conference Call Scheduled for 10:00 a.m. ET Today SOUTH SAN FRANCISCO, Calif., Jan. 14 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. (Nasdaq: CEGE ) today announced that the Independent Data Monitoring Committee (IDMC) for VITAL-1, the first of two ongoing Phase 3 clinical trials of...

Cell Genesys Provides Final Median Survival Data From Second Phase 2 Trial of GVAX Immunotherapy for Prostate Cancer

SOUTH SAN FRANCISCO, Calif., April 03, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today announced final, updated results from its second multi-center Phase 2 trial of GVAX immunotherapy for prostate cancer which evaluated escalating doses of the immunotherapy in 80 patients with metastatic ...

Cell Genesys Reports GVAX Immunotherapy for Prostate Cancer Induces a Broad, Patient-Specific Antibody Response

SOUTH SAN FRANCISCO, Calif., April 17, 2007 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported immune response data from two previously conducted Phase 2 clinical trials of GVAX immunotherapy for prostate cancer. Evaluation of antibody responses in patients with advanced prostate cancer f...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

...state Cancer Session) -- Oral presentation beginning at 11:30 a.m. local time on Monday, June 2, 2008. -- "Expanded phase 1 combination trial of gvax immunotherapy for prostate cancer and ipilimumab in patients with metastatic hormone-refractory prostate cancer (mHRPC)" (Abstract #5146, Geni...

Medarex Reports Interim Data from Ongoing Ipilimumab Combination Phase 1 Studies in Prostate Cancer at American Association for Cancer Research Meeting

... hormone-refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimum...limumab in combination with the Cell Genesys, Inc. gvax immunotherapy for prostate cancer (an investig...nsion cohort (3 mg/kg ipilimumab). The dose of gvax immunotherapy for prostate cancer used in this...

Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer

...ed follow-up data from a Phase 2 clinical trial of gvax immunotherapy for pancreatic cancer which was cond...ients with operable pancreatic cancer who received gvax after surgical resection of their tumor and adjuva...ent surgery and adjuvant therapy without receiving gvax indicated that the median overall survival of the ...
GVAX in Biological News

Combination therapy with a monocloncal antibody and a vaccine leads to tumor rejection

...eration and allows both Tregs and Teff cells to proliferate in response to exposure to self-antigen. Interestingly, combination of CLTA4 blockade with gvax selectively primes the anti-tumor Teff cells for action. This led to greater infiltration of Teff cells into the tumor, and eventually to tumor reject...
GVAX in Biological Technology

New Report Just Published: World Prostate Cancer Therapeutics Market Report

...n Bavituximab in Prostate Cancer II-54 Cell Genesys Reveals Data of gvax Immunotherapy for Treatment of Prostate Cancer II-54 Bioponic Phyto...to Take Over Rights of a New Marker Technology II-78 Cell Genesys's gvax Prostate Cancer-Treatment Attains FDA's Fast Track Tag II-78 Envisi...

Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research

...pril 12-16, 2008 in San Diego: -- "Dendritic and T cell functions in patients with metastatic hormone- refractory prostate cancer treated with gvax immunotherapy for prostate cancer and ipilimumab" (Abstract #2538, Clinical Immunotherapy Session) - Oral presentation scheduled for Monday, A...

Cell Genesys to Present at the BIO CEO and Investor Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys Announces Sale of Lentiviral Gene Delivery Technology for $12 Million

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Webcast Third Quarter 2007 Conference Call

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Cell Genesys to Present at the BIO Investor Forum

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...

Emergence of Cancer Vaccines Will Be the Key Factor Driving the Pancreatic Cancer Drug Market to More Than Double by 2016

...c cancer drug market to more than double by 2016. The new Pharmacor report entitled Pancreatic Cancer finds that Pharmexa's GV1001 and Cell Genesys's gvax will drive the market from $560 million in 2006 to $1.2 billion in 2016 in the United States, France, Germany, Italy, Spain, United Kingdom and Japan....

Cell Genesys to Present at the Bear Stearns 20th Annual Healthcare Conference

...ncolytic virus therapies. Ongoing clinical trials include Phase 3 trials of gvax immunotherapy for prostate cancer, Phase 2 trials of gvax immunotherapies for pancreatic cancer and for leukemia, and a Phase 1 trial...
Other Tags
(Date:9/23/2014)... The Fit Body Boot Camp franchise is known throughout ... and their community outreach. The new Rockville Fit Body Boot ... of the company’s new fitness boot camp in ... is excited about the grand opening, because of the opportunity ... honor the memory of emergency workers who sacrificed their lives ...
(Date:9/23/2014)... 2014 Maturo Medical Weight and ... announced Dr. Lisa Maturo has received certification in ... Worldlink Medical Academy. Dr. Maturo is one of ... this credential. , World-renowned bioidentical hormone replacement ... the rigorous training course, which trained participants in ...
(Date:9/23/2014)... 23, 2014 Wohl Associates ... packaging equipment, has recently taken delivery of used industrial ... include mixers, sheeters, and equipment for producing gnocchi and ... Toresani unit and a La Parmigiana mixer/extruder. With a ... a mixing tank that is 17” wide, 28” long ...
(Date:9/23/2014)... 23, 2014 Hope For The Warriors® ... Celebration to be hosted in Boston, Massachusetts on Sunday, ... Amphitheater. This signature event honors the courage of our ... the fallen. Proceeds from the evening will benefit Hope ... a sense of self, restoring the family unit, and ...
(Date:9/23/2014)... Los Angeles, CA (PRWEB) September 23, 2014 ... launched sales funnel building software application has created a ... commotion surrounding the launch of this new software has ... published an investigative review for her readers. ... such as site design, programming and development can be ...
Breaking Medicine News(10 mins):Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 2Health News:Rockville Fit Body Boot Camp Invites Community to Fitness Boot Camp Grand Opening 3Health News:Doctor Lisa Maturo of Maturo Medical Obtains Expert Certification in BioIdentical Hormone Replacement Therapy from World Link Medical 2Health News:Used Industrial Pasta Machinery Now Available at Wohl Associates 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 2Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Boston 3Health News:ClickFunnels 2.0 – Review Of Russell Brunson’s Sales Funnel Building Software Released 2
(Date:9/22/2014)... 2011 the Society of Environmental Toxicology and Chemistry (SETAC) ... and prioritize the scientific research needed to understand the ... the environment. The effort was extended, and results ... Society,s international journal, Integrated Environmental Assessment and Management ... a podcast interviewing the lead author of the study, ...
(Date:9/22/2014)... Additive manufacturing (AM), or 3D printing, has rapidly ... metal components strong enough for structural applications. However, ... as well as quality standards to test the ... technology. Engineers at the University of Pittsburgh,s Swanson ... modeling and simulation (M&S) technology and new qualification ...
(Date:9/22/2014)... and larger areas of sea ice melt in the summer ... it is thinner and more reduced. As the Arctic summers ... warming, because reduced sea ice in the Arctic will remove ... our results are representative, then sea ice plays a greater ... in future global CO2 budgets", says Dorte Haubjerg Sgaard, PhD ...
Breaking Biology News(10 mins):Priorities for research on pharmaceutical and personal care products in the environment 2Pitt engineers receive grants to enhance additive manufacturing 2Pitt engineers receive grants to enhance additive manufacturing 3Arctic sea ice helps remove CO2 from the atmosphere 2
Other Contents